Takeda Joins Structural Genomics Consortium

April 6, 2012

April 6, 2012 | Takeda Pharmaceutical has joined the Structural Genomics Consortium (SGC), a public-private partnership that supports the discovery of new medicines through open access research. SGC is based at the Universities of Toronto, Canada, and Oxford, England and consisting of six pharma companies. Takeda's contribution raises the SGC's funds to $50 million. The SGC's research network helps Takeda promote its drug discovery efforts by accessing new research first hand. The company also can influence the research direction of the SGC network by participating on the SGC Scientific Committee and its Board of Directors. Press release